---
title: "Natera 的股票能否達到 500 美元？"
description: "Natera（納斯達克代碼：NTRA）經歷了顯著增長，其股價從首次公開募股時的 18 美元上漲至約 170 美元，收入從 1.9 億美元擴大至 20 億美元。該公司專注於分子診斷，特別是通過其產品 Signatera 進行癌症檢測，該產品利用血液檢測監測腫瘤 DNA。Natera 在上個季度處理了超過 85 萬次檢測，產生了 5.466 億美元的收入，腫瘤學檢測同比增長 50%。分析師預測，Nat"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257398659.md"
published_at: "2025-09-15T14:34:49.000Z"
---

# Natera 的股票能否達到 500 美元？

> Natera（納斯達克代碼：NTRA）經歷了顯著增長，其股價從首次公開募股時的 18 美元上漲至約 170 美元，收入從 1.9 億美元擴大至 20 億美元。該公司專注於分子診斷，特別是通過其產品 Signatera 進行癌症檢測，該產品利用血液檢測監測腫瘤 DNA。Natera 在上個季度處理了超過 85 萬次檢測，產生了 5.466 億美元的收入，腫瘤學檢測同比增長 50%。分析師預測，Natera 可能維持 25% 的年收入增長，到 2030 年有望達到 70 億美元，這可能推動股價超過 500 美元

Cancer detection and screening as a treatment for malignant cells with a biopsy or testing caused by carcinogens and genetics with a cancerous cell as an immunotherapy symbol as a 3D render. getty Let's start with something remarkable. Natera (NASDAQ: NTRA) just marked its 10th anniversary as a public company, and what a journey it has been. The stock has delivered nearly 10x returns, rising from its $18 IPO price to around $170 today. Even more impressive, revenues have also expanded about 10-fold from $190 million to $2 billion. And the momentum hasn’t slowed — revenue growth over the last twelve months was a stellar 44%. So, what’s fueling this growth? It comes down to one word: intelligence — specifically, medical intelligence. Natera has placed itself at the forefront of molecular diagnostics, especially in cancer detection and monitoring. Think of them as medical detectives, helping doctors detect issues at the genomic level before they become life-threatening emergencies. Their flagship product, Signatera, is a game-changer. This personalized tumor-informed test uses a simple blood draw to detect circulating tumor DNA and monitor for molecular residual disease across multiple cancer types, including breast, lung, ovarian, colorectal, and bladder cancers. This isn’t just an incremental improvement — it’s a revolutionary technology transforming how oncologists monitor their patients. But what makes their technology stand out? Its beauty lies in its simplicity and precision. Rather than invasive procedures, patients undergo a simple blood draw — a liquid biopsy. But this isn’t an ordinary blood test. Natera’s platform can detect tiny fragments of tumor DNA circulating in the bloodstream, offering doctors unprecedented insight into cancer progression and recurrence risk. Beyond Signatera, Natera also offers Altera for genomic profiling and Empower for hereditary cancer screening — creating a comprehensive suite that covers the entire cancer care spectrum. Before we dive into Natera stock’s specific metrics, it’s worth noting an important reality: investing in high-growth companies like Natera comes with volatility. While the upside can be significant, the ride is often bumpy. If you want high-quality growth with lower volatility than a single stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark — a blend of the S&P 500, Russell, and S&P MidCap indexes — with returns exceeding 91% since inception. This diversified approach provides exposure to high-quality growth names while managing single-stock risk. On a separate note, see – What’s Happening With ABBV Stock? MORE FOR YOU Now, let’s explore why Natera’s story is so compelling. Here’s where things get exciting. In the latest quarter, Natera processed over 850,000 tests, generating $546.6 million in revenue. About 22% of these tests were oncology-related, and this segment is growing at 50% year-over-year. This is the key engine driving future growth. Let’s zoom out. Cancer recurrence is every survivor’s worst fear, yet traditional monitoring often leaves patients waiting months for clarity. Nearly 19 million U.S. cancer survivors live in constant uncertainty between scans. They need better tools to track their cancer status, representing a massive market that will require sophisticated monitoring for decades to come. Now, we believe Natera can sustain 25% annual revenue growth over the next few years. That would boost revenue from about $1.7 billion last year to around $7 billion in 2030 — a 4x increase. For context, they’ve grown revenue at an average of 40% over the past three years, so 25% is actually not that aggressive. You might ask — is there room for a company this size to keep growing? Absolutely. The cell-free DNA testing market — which includes what Signatera does — is expected to almost double from $11 billion today to around $20 billion within five years. \[1\] Natera isn’t just riding this wave — they’re helping shape it. Consider the competition: Roche leads diagnostics with $16+ billion in revenue, followed by Danaher at $10 billion and Abbott at $9 billion. Natera’s $2 billion shows they’re still in the early innings of their growth story. The growth path breaks down into several key areas: How could $7 billion in revenue translate to a $500+ stock price? The math is compelling. If Natera hits $7 billion while maintaining its current price-to-sales multiple of 13x, the stock could reach about $700. Even with multiple compressions to 10x, that’s still well above $500. This assumes minimal dilution, which is reasonable given its cash-generation potential at scale. Yes, the company is currently loss-making, but as revenue grows, margins should turn positive. Natera’s net income margin has improved from -75% in 2021 to -13% now. Diagnostic market penetration takes time. For Natera to be valued at $50B, $100B, or even $200B (vs. $23B today), investors must think long-term — 2030 and beyond — with billions of tests processed annually worldwide. By 2035, liquid biopsies could be as routine as cholesterol tests. Still, several factors must align: Despite the opportunity, key risks remain: Natera is a genuine growth story driven by breakthrough technology addressing massive markets. It has scaled impressively while sustaining momentum that most CEOs would envy. The path to $500+ per share is mathematically feasible — but execution must be flawless. For risk-tolerant investors, this offers high growth with meaningful upside — balanced by real execution and market risks. For a more diversified approach, the Trefis Reinforced Value (RV) Portfolio has outperformed its benchmark of the S&P 500, S&P MidCap, and Russell 2000. Its quarterly rebalanced mix of large-, mid-, and small-cap names has delivered strong returns while cushioning losses in down markets (RV Portfolio metrics). The opportunity is real — the question is whether Natera can execute and whether investors can stomach the volatility for what could be a rewarding ride.

### Related Stocks

- [NTRA.US - Natera](https://longbridge.com/zh-HK/quote/NTRA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Natera 發佈 AI 模型以增強癌症復發風險預測能力 | Natera Inc. 推出了一個新的多模態人工智能模型，旨在通過分子殘留疾病（MRD）評估來改善癌症復發風險預測。該模型結合了循環腫瘤 DNA、臨牀數據、數字病理影像和腫瘤測序數據，利用了大約 30 萬名患者的數據庫。展示顯著提升的結果將 | [Link](https://longbridge.com/zh-HK/news/272415523.md) |
| Natera 在 ASCO GI 會議上展示了 ALTAIR 臨牀試驗的最新分析 \| NTRA 股票新聞 | Natera, Inc.（納斯達克代碼：NTRA）宣佈了來自 ALTAIR 臨牀試驗的最新分析結果，顯示在 Signatera 陽性患者中，I-IV 期結直腸癌的無病生存期（DFS）具有統計學顯著性。試驗結果將在 2026 年 1 月的 A | [Link](https://longbridge.com/zh-HK/news/271579188.md) |
| 在 Once Upon a Farm 首次公開募股後，是否應該購買 OFRM 股票？ | 在 Once Upon a Farm 上市後，您應該購買 OFRM 股票嗎？ | [Link](https://longbridge.com/zh-HK/news/275353526.md) |
| 印度的 Rays Of Belief 提交了更新的 IPO 草案文件 - UDRHP | 印度的 RAYS OF BELIEF 提交了 IPO 的更新草案文件 - RAYS OF BELIEF IPO：新發行規模為 600 萬股，沒有出售要約 | [Link](https://longbridge.com/zh-HK/news/275733120.md) |
| 據報道，Clear Street 因市場狀況推遲了首次公開募股（IPO） | Clear Street Group 因市場條件不佳，已將原定於 2 月 13 日的首次公開募股（IPO）推遲。該公司將其股票發行量減少了超過 50%，並將價格區間下調了約 36%，這將使其估值約為 72 億美元，而非預期的 120 億美元 | [Link](https://longbridge.com/zh-HK/news/275905551.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。